Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Acotec Scientific Holdings's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 6.76%.
As of today (2026-09-03), Acotec Scientific Holdings's WACC % is 8.36%. Acotec Scientific Holdings's ROC % is -4.67% (calculated using TTM income statement data).
Acotec Scientific Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Acotec Scientific Holdings's WACC % is 8.36%. Acotec Scientific Holdings's ROC % is -4.67% (calculated using TTM income statement data).
Acotec Scientific Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acotec Scientific Holdings (HKSE:06669) has a ROC % of 6.76% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Acotec Scientific Holdings and its competitors.
Is Acotec Scientific Holdings' ROC % too high?
Acotec Scientific Holdings' current ROC % is 6.76%. The Medical Devices & Instruments industry median ROC % is 1.63. Acotec Scientific Holdings' value of 6.76% is 314.7% above this industry median. Overall, Acotec Scientific Holdings has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acotec Scientific Holdings' ROC % compare to ABT and SYK?
Acotec Scientific Holdings' ROC % of 6.76% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.63. Acotec Scientific Holdings' value of 6.76% is 314.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.63, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acotec Scientific Holdings's current ROC % of 6.76% is 314.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Acotec Scientific Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acotec Scientific Holdings's current ROC % is 6.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acotec Scientific Holdings stock overvalued right now?
Based on GuruFocus' analysis, Acotec Scientific Holdings (HKSE:06669) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.83, compared to a current price of HK$6.37 — trading 57.1% below its estimated fair value. The current ROC % is 6.76% and 314.7% above the Medical Devices & Instruments industry median of 1.63. Acotec Scientific Holdings' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Acotec Scientific Holdings (HKSE:06669), the current ROC % is 6.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acotec Scientific Holdings (HKSE:06669) Overvalued in 2026?
Based on GuruFocus' analysis, Acotec Scientific Holdings stock appears to be undervalued.
The current stock price of HK$6.37 is trading 57.1% below its estimated GF Value™ of HK$14.83.
GuruFocus considers Acotec Scientific Holdings to be Significantly Undervalued.
Key valuation signals for HKSE:06669:
ROC %: 6.76%
GF Value™: HK$14.83 vs. price of HK$6.37 (57.1% below fair value)
Industry Position: 314.7% above the Medical Devices & Instruments median
No single metric tells the full story. See the HKSE:06669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acotec Scientific Holdings Ltd is a medical technology company, focusing on the research and development, and application of technology platforms in the field of vascular interventional treatment. Its product portfolio comprises Semi-compliant PTCA balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), Coronary CTO Antegrade Micro-Catheter (Vericor-14), Coronary High-Pressure Balloon (YIYAN), Coronary CTO Retrograde Micro-Catheter (Vericor-RS), Cardiac Valve Balloon Dilation Catheter (RunFlow), etc., and also has various other products in its development pipeline. Geographically, the company generates a majority of its revenue from Mainland China, and the rest from other regions. The firm generates the majority of its revenue from sales to Domestic distributors.
76GF Score
Get the complete analysis for HKSE:06669
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06669 has been successfully added to your 
